20.500.12556/DiRROS-18737 Do double-expressor high-grade B-cell lymphomas really need intensified treatment a report from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology Ljubljana High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients. lymphoma double-expressor lymphoma oncology limfomi dvojno izražen limfom onkologija true false true MDPI Basel, Switzerland Angleški jezik Slovenski jezik by Authors Neznano 2024-04-18 13:53:08 2024-04-18 13:53:09 2024-05-14 11:01:59 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 5. 2. 2024; str. 275-1-275-13 no. 2 Vol. 12 2024 0000-00-00 Zaloznikova Objavljeno apc 2023-12-25 2024-01-22 2024-01-25 616.4 2227-9059 10.3390/biomedicines12020275 183791619 https://www.mdpi.com/2227-9059/12/2/275 1 77efdea7-fd69-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25639 RAZ_Boltezar_Lucka_2024.pdf RAZ_Boltezar_Lucka_2024.pdf 1 0B65236A0D9289CF428EF4900DDF9FCC d822af25e7192ad1553a206801163072066289b22f67143573d1891876fc11ba 7a9f4a3d-fd6a-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25640 Onkološki inštitut Ljubljana 0 0 0